Forsta AP Fonden Has $13.14 Million Holdings in Insulet Corporation $PODD

Forsta AP Fonden lifted its holdings in Insulet Corporation (NASDAQ:PODD) by 53.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,220 shares of the medical instruments supplier’s stock after acquiring an additional 16,120 shares during the period. Forsta AP Fonden owned approximately 0.07% of Insulet worth $13,138,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Glenmede Investment Management LP grew its stake in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares in the last quarter. Curi Capital LLC lifted its position in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the period. WINTON GROUP Ltd lifted its position in Insulet by 0.9% during the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 37 shares during the period. Camarda Financial Advisors LLC lifted its position in Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after purchasing an additional 40 shares during the period. Finally, Larson Financial Group LLC lifted its position in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the period.

Insulet Price Performance

PODD stock opened at $144.94 on Monday. The stock has a market capitalization of $10.04 billion, a P/E ratio of 33.71, a price-to-earnings-growth ratio of 1.14 and a beta of 1.13. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12 month low of $140.63 and a 12 month high of $354.88. The firm has a 50-day moving average price of $183.55 and a 200-day moving average price of $244.77.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts anticipate that Insulet Corporation will post 6.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PODD. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $280.00 price objective on shares of Insulet in a research report on Wednesday, May 27th. Oppenheimer cut their price objective on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Citigroup cut their price objective on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday. Bank of America cut their price objective on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Finally, Wells Fargo & Company cut their price objective on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.